You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):集團擬以15.96億元轉讓亞能生物29.02%股權及金石醫檢所100%股權
格隆匯 09-30 18:05

格隆匯9月30日丨復星醫藥(600196.SH)公佈,集團擬以人民幣15.96億元的對價轉讓所持有(1)亞能生物合計29.0200%的股權、(2)金石醫檢所100%股權;同時,本次交易的買方Yaneng Bioscience擬出資人民幣3億元認繳亞能生物新增註冊資本63.46萬港元。

2021年9月30日,控股子公司亞能生物及其現有股東(即復星醫藥、亞能投資、前海志投,下同)與買方共同簽訂《股權轉讓及增資協議》;同日,公司、控股子公司亞能生物、亞能投資與Yaneng Bioscience簽訂《股東協議》。

根據約定,(1)亞能生物現有股東擬以合計人民幣22.04億元的對價向買方轉讓出售權益(以下簡稱“本次轉讓”),(2)Yaneng Bioscience擬出資人民幣3億元認繳亞能生物新增註冊資本63.46萬港元(以下簡稱“本次增資”)

於本次轉讓中,集團擬以人民幣15.96億元的對價向買方轉讓所持有的亞能生物29.0200%的股權以及向買方與亞能生物共同指定的主體轉讓所持有的金石醫檢所100%的股權;亞能投資、前海志投擬分別以人民幣4.356億元、1.72億元向買方轉讓所持有的亞能生物7.9200%、3.1325%的股權。

本次交易(即本次轉讓及本次增資)對價以目標集團整體估值人民幣55億元為基礎確定,該等估值約相當於目標集團2020年淨利潤的26.6倍(P/E倍數)。

此次交易完成後,集團持有亞能生物的股權比例將由50.1084%降至19.9976%,亞能生物將由公司之控股子公司轉為聯營公司;集團將不再持有金石醫檢所的股權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account